Saturday, November 11, 2006 12:50:12 PM
"We undertake no obligation to update or revise the information provided in this call, whether as the result of new information,
future events or otherwise. Before I make the introductions, I would like to state that the patents litigation trials of Genentech
and Tercica vs. Insmed will begin in Oakland, California on Monday, November 6, in the Northern District Court of the U.S. Circuit
Court. Therefore, we will not be making any comments on this litigation.
It is now my pleasure to introduce you to the participants in today's call: Dr. Geoffrey Allan, the President and Chief Executive
Officer at Insmed; Kevin Tully, Chief Financial Officer; and Philip Young, Chief Business Officer. It's now my pleasure to turn the
call over to Dr. Geoffrey Allan for opening remarks. Geoff?
Dr. Geoffrey Allan - Insmed Incorporated - Chairman, CEO, President
Thank you, Jody. Good morning, everybody and thank you for joining the call this afternoon. Insmed has enjoyed a very
productive third quarter result as well as year-to-date for 2006. Let me briefly review some of the year's activities before passing
over to some of the management here for more detailed presentation.
Since we launched IPLEX to the pediatric endocrine market late in the second quarter, we have been gratified to witness a good
physician adoption for the growing number of children on therapy. Still, we'll update you on our progress in a moment.
We continued our label expansion studies for IPLEX and now we have ongoing clinical studies where we are evaluating the
value of IPLEX in several disease areas, such as severe insulin resistance, myotonic muscular dystrophy, AIDS [unintelligible]
dystrophy and we're about to initiate a new clinical study in children with Newman's Syndrome.
Positive data from our severe insular resistance study and our pivotal IGFD studies were presented at several [unintelligible] of
the Congress this last quarter and we hope to present top-line data from these new studies in the first half of 2007.
In the second quarter, we also submitted our European market application. THE EMEA has validated and accepted our application
and we anticipate working with this agency to gain approval in 2007. I am happy to say that we are making all of this progress
while staying within the financial guidance provided to you earlier this year and Kevin will provide more detail of our financial
performance in a moment.
So with that very brief overview, I will now pass on to Phil to present our business results. Phil?"
http://preview.tinyurl.com/y2hm6x
PY comments in more detail and is doing Q&A session with Osborne, as written in earlier post! Please read trial approved transcript!
Jody was NOT at R&R! PY was presenting! Only PY.
CF
Recent INSM News
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/12/2024 08:05:02 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/12/2024 08:01:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 09:30:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 11:00:26 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 11:00:05 AM
- Insmed Reports Second-Quarter 2024 Financial Results and Provides Business Update • PR Newswire (US) • 08/08/2024 11:00:00 AM
- Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 08/02/2024 12:00:00 PM
- Insmed to Host Second-Quarter 2024 Financial Results Conference Call on Thursday, August 8, 2024 • PR Newswire (US) • 07/29/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/10/2024 09:19:37 PM
- Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 07/05/2024 12:00:00 PM
- Additional Positive Data from Pivotal ASPEN Study of Brensocatib in Patients with Bronchiectasis to be Presented at the 7th World Bronchiectasis Conference • PR Newswire (US) • 07/03/2024 01:03:00 PM
- Insmed Announces Redemption of all $225 Million of Outstanding 1.75% Convertible Senior Notes Due 2025 • PR Newswire (US) • 06/27/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 12:00:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/12/2024 08:21:15 PM
- Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 06/07/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/05/2024 08:23:25 PM
- Insmed To Present at the Goldman Sachs 45th Annual Global Healthcare Conference • PR Newswire (US) • 06/05/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:00:43 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/03/2024 08:33:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 09:46:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 09:45:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 09:44:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 09:43:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 09:41:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/30/2024 09:32:49 PM
Kona Gold Beverages, Inc. Nears Completion of Reverse Merger with New Candidate • KGKG • Aug 12, 2024 10:00 AM
Maybacks Global Entertainment and DigiTrax Entertainment Sign Agreement to Broadcast "Karaoke Cloud" on iDreamCTV • AHRO • Aug 12, 2024 8:45 AM
HealthLynked Partners with RxSpark to Enhance Medication Access and Management for Patients • HLYK • Aug 12, 2024 8:00 AM
Maybacks Global Entertainment and ZEASN Technology Private Ltd. Sign Global Licensing Agreement • AHRO • Aug 8, 2024 7:00 AM
SANUWAVE Will Host a Conference Call on August 13, 2024 at 8:30 AM (ET) to Present Q2 Financial Results • SNWV • Aug 8, 2024 6:59 AM
Kona Gold Beverage Inc. Signs Letter of Intent with Bemax, Inc. to Sell Kona Gold, LLC • BMXC • Aug 7, 2024 10:00 AM